-
Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, November 7, 2022 — Novartis today announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-C) reduction over a four-year period in patients with either atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent, and elevated LDL-…Reimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, October 14, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617), a…Reimagine MedicineOncologyMedical InnovationsCancer
-
Ad hoc announcement pursuant to Art. 53 LRScientific DiscoveriesReimagine MedicineMedical InnovationsAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Access to HealthcareGlobal Health PartnershipsMedical InnovationsOncologySocial Commitment
-
Basel, June 22, 2022 — Novartis announced today that the European Commission (EC) approved Tabrecta® (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy…Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, June 6, 2022 — Novartis today announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma (pLGG) requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients1. In this study, patients…Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, June 3, 2022 — Novartis today announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect treatment benefit with Piqray® (alpelisib) plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor-…Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, June 3, 2022 — Novartis today announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer. These data will be presented at the…Reimagine MedicineOncologyMedical InnovationsCancer